Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | EVP, Chief Financial Officer | July 30, 2026 | August 03, 2026 |
| TerrAscend Corp.TSNDF · Entity 6184 | Director | June 24, 2025 | June 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HERON THERAPEUTICS, INC. /DE/
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 281,899 |
Ending reported balance
After 2026-07-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-30 · Exercise / conversion · Acquired 13,535 · Balance 277,381 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 2 · 2026-07-30 · Tax withholding · Disposed 3,850 · Balance 273,531 Row 3 · 2026-07-31 · Exercise / conversion · Acquired 11,694 · Balance 285,225 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 4 · 2026-07-31 · Tax withholding · Disposed 3,326 · Balance 281,899 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 189,492 |
Reported balance
After 2026-07-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-30 · Exercise / conversion · Disposed 13,535 · Balance 189,492 F2: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 116,944 |
Reported balance
After 2026-07-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-31 · Exercise / conversion · Disposed 11,694 · Balance 116,944 F3: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
F2: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.
F3: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).
TerrAscend Corp.
Report date June 24, 2025 · Filed June 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 657,930 |
Reported balance
After 2025-06-24 transaction · row 1
1 source rowRow 1 · 2025-06-24 · Grant · Acquired 433,653 · Balance 657,930 F1: These shares represent a restricted share unit ("RSU") award for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2025, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent a restricted share unit ("RSU") award for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2025, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 3, 2026 13:50 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 11,694 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-329720 · ownership.xml · derivative · entry 6 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,944 Underlying: Common Stock · 11,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 13:50 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 3,326 | $0.50 | $1,663.00 |
DisclosureSEC source: 0001193125-26-329720 · ownership.xml · nonDerivative · entry 4 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,899 Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 13:50 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 11,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-329720 · ownership.xml · nonDerivative · entry 3 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 13:50 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 13,535 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-329720 · ownership.xml · derivative · entry 5 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,492 Underlying: Common Stock · 13,535 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. F2 · derivative.expiration_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 13:50 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 3,850 | $0.50 | $1,925.00 |
DisclosureSEC source: 0001193125-26-329720 · ownership.xml · nonDerivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,531 Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 13:50 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 13,535 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-329720 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| July 19, 2026 Filed Jul 20, 2026 19:54 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,874 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-308887 · ownership.xml · derivative · entry 3 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,246 Underlying: Common Stock · 3,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| July 19, 2026 Filed Jul 20, 2026 19:54 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 1,101 | $0.47 | $517.47 |
DisclosureSEC source: 0001193125-26-308887 · ownership.xml · nonDerivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,846 Read SEC document |
| July 19, 2026 Filed Jul 20, 2026 19:54 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,874 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-308887 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 14:52 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-273552 · ownership.xml · derivative · entry 3 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 14:52 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 3,555 | $0.38 | $1,350.90 |
DisclosureSEC source: 0001193125-26-273552 · ownership.xml · nonDerivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,073 Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 14:52 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-273552 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 30, 2026 Filed May 4, 2026 15:56 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 13,535 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-203272 · ownership.xml · derivative · entry 4 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,027 Underlying: Common Stock · 13,535 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. F4 · derivative.expiration_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. Read SEC document |
| April 30, 2026 Filed May 4, 2026 15:56 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 11,694 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-203272 · ownership.xml · derivative · entry 3 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,638 Underlying: Common Stock · 11,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| April 30, 2026 Filed May 4, 2026 15:56 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 13,535 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-203272 · ownership.xml · nonDerivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · balance_after: Includes 11,023 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2026. Read SEC document |
| April 30, 2026 Filed May 4, 2026 15:56 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 11,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-203272 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 19, 2026 Filed Apr 21, 2026 13:13 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,874 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-165304 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,120 Underlying: Common Stock · 3,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| April 19, 2026 Filed Apr 21, 2026 13:13 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,874 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-165304 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · balance_after: Includes 16,646 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 13:30 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 11,695 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034492 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,332 Underlying: Common Stock · 11,695 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 13:30 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 11,695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-034492 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 15:00 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantPerformance Stock Units · Derivative | 216,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034630 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,561 Underlying: Common Stock · 216,561 shares Expires not disclosed F3 · derivative.exercise_price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On January 30, 2026, the Reporting Person was granted 216,561 PSUs which vest upon the following time-based vesting schedule: the PSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant, subject to satisfaction of the milestone-based vesting condition: the applicable percentage of the PSUs vesting based on a net product sales revenue target for the fiscal year ending December 31, 2026 as reported in the Issuer's Form 10-K. The full amount of the PSUs granted to the Reporting Person is reflected herein. F4 · derivative.expiration_date: On January 30, 2026, the Reporting Person was granted 216,561 PSUs which vest upon the following time-based vesting schedule: the PSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant, subject to satisfaction of the milestone-based vesting condition: the applicable percentage of the PSUs vesting based on a net product sales revenue target for the fiscal year ending December 31, 2026 as reported in the Issuer's Form 10-K. The full amount of the PSUs granted to the Reporting Person is reflected herein. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 15:00 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantRestricted Stock Units · Derivative | 216,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034630 · ownership.xml · derivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,562 Underlying: Common Stock · 216,562 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein. F2 · derivative.expiration_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein. Read SEC document |
| January 19, 2026 Filed Jan 20, 2026 19:49 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-016423 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,994 Underlying: Common Stock · 3,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| January 19, 2026 Filed Jan 20, 2026 19:49 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-016423 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 17:33 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 11,694 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-264039 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,027 Underlying: Common Stock · 11,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 17:33 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 11,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-264039 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| October 19, 2025 Filed Oct 21, 2025 15:42 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,874 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-244560 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,869 Underlying: Common Stock · 3,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| October 19, 2025 Filed Oct 21, 2025 15:42 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,874 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-244560 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| July 31, 2025 Filed Aug 4, 2025 21:27 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 11,695 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-102158 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,721 Underlying: Common Stock · 11,695 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The number of restricted stock units disclosed on the Reporting Person's Form 4 filed on April 22, 2025, May 2, 2025 and June 17 , 2025 ("Affected Form 4 Filings") were erroneously disclosed as an acquisition in Column 5(A) when it should have been disclosed as a disposition in Column 5(D). All other information in the Affected Form 4 Filings is correct. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| July 31, 2025 Filed Aug 4, 2025 21:27 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 11,695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-102158 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| July 19, 2025 Filed Jul 22, 2025 16:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,874 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-097498 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,743 Underlying: Common Stock · 3,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| July 19, 2025 Filed Jul 22, 2025 16:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,874 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-097498 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 24, 2025 Filed Jun 25, 2025 20:55 UTC | TerrAscend Corp. TSNDF · Entity 6184 | GrantCommon Shares | 433,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-018193 · form4-06252025_080616.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 657,930 F1 · shares: These shares represent a restricted share unit ("RSU") award for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2025, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. Read SEC document |
| June 16, 2025 Filed Jun 17, 2025 21:53 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087534 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 16, 2025 Filed Jun 17, 2025 21:53 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-087534 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:32 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 11,694 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-063063 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,416 Underlying: Common Stock · 11,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:32 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 11,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-063063 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 19, 2025 Filed Apr 22, 2025 13:57 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-056492 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,617 Underlying: Common Stock · 3,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| April 19, 2025 Filed Apr 22, 2025 13:57 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-056492 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 17:44 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantRestricted Stock Units · Derivative | 187,110 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013044 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,110 Underlying: Common Stock · 187,110 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 17:44 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 374,220 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000950170-25-013044 · ownership.xml · derivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,220 Underlying: Common Stock · 374,220 shares Expires 2035-01-31 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (January 31, 2025). Read SEC document |
| January 19, 2025 Filed Jan 22, 2025 14:32 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,874 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-007557 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,492 Underlying: Common Stock · 3,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| January 19, 2025 Filed Jan 22, 2025 14:32 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,874 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-007557 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · balance_after: Includes 8,705 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2024. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:04 UTC | TerrAscend Corp. TSNDF · Entity 6184 | Tax withholdingCommon Shares | 71,704 | $0.65 | $46,607.60 |
DisclosureSEC source: 0001415889-25-000381 · form4-01032025_090143.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,277 F1 · shares: Shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted share units pursuant to an equity plan administered by the Issuer. Read SEC document |
| October 19, 2024 Filed Oct 21, 2024 19:55 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,874 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-115927 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,366 Underlying: Common Stock · 3,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| October 19, 2024 Filed Oct 21, 2024 19:55 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,874 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-115927 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| July 19, 2024 Filed Jul 22, 2024 13:32 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-085089 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,240 Underlying: Common Stock · 3,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| July 19, 2024 Filed Jul 22, 2024 13:32 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-085089 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:30 UTC | TerrAscend Corp. TSNDF · Entity 6184 | GrantCommon Shares | 163,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017689 · form4-06202024_050608.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,981 F1 · shares: These shares represent a restricted share unit ("RSU") award for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2024, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. Read SEC document |
| June 16, 2024 Filed Jun 17, 2024 18:21 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074168 · ownership.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.